Sudeep Pharma Q4FY26 Revenue Up 16% YoY

Sudeep Pharma reported Q4FY26 revenue of ₹182.3 Cr, up 16% YoY, and FY26 revenue of ₹642.3 Cr, its highest ever.
The company acquired 85% stake in NSS via subsidiary, expanding European presence and advanced formulation capabilities.
Groundbreaking held for ₹300 Cr Dahej battery materials plant (25,000 MT Phase 1) targeting early CY27 commissioning.
Q4 margins compressed to 34.3% EBITDA due to raw material inflation and West Asia conflict supply disruptions.